Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders

Haematologica

Volumn 89, Issue 5, 2004, Pages 520-527

  Birgegård, Gunnar ^a   Björkholm, Magnus ^b   Kutti, Jack ^c   Lärfars, Gerd ^d   Löfvenberg, Eva ^e   Markevärn, Berit ^e   Merup, Mats ^b   Palmblad, Jan ^b   Mauritzson, Nils ^g   Westin, Jan ^f   Samuelsson, Jan ^d  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d STOCKHOLM SÖDER HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g NONE

Author keywords

Anagrelide; Myeloproliferative disease; Thrombocythemia

Indexed keywords

ANAGRELIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG CAPSULE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HEART PALPITATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NAUSEA; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; PHYSICIAN; POLYCYTHEMIA VERA; PROSPECTIVE STUDY; RATING SCALE; SIDE EFFECT; SWEDEN; SYMPTOM; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TREATMENT FAILURE;

EID: 2542419052     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Pearson TC, Messinezy M, Westwood N, Green AR, Bench AJ, Huntly BJ, et al. Polycythemia vera Updated: diagnosis, pathobiology, and treatment. Hematology (Am Soc Hematol Educ Program) 2000;51-68.
2. Pearson TC, Bareford D, Craig J, Egan EL, Green AR, Lucas GS, et al. The management of 'low-risk' and 'intermediate-risk' patients with primary thrombocythaemia. MPD (UK) Study Group. Br J Haematol 1999;106:833-4.
3. Gilbert HS. Historical perspective on the treatment of essential thrombocythemia and polycythemia vera. Semin Hematol 1999;36:19-22.
4. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD and Berlin NI, editors. Polycythemia Vera and the Myeloproliferative disorders. WB Saunders; Philadelphia: USA. 1995. p. 166-94.
5. Tefferi A. Current management of polycythemia vera. Leuk Lymphoma 2002;43:1-7.
6. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110:577-83.
7. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol 2003;74:26-31.
8. Merup M, Åberg W, Löfvenberg E, Svensson E, Engman K, Paul C, et al. Symptoms, symptom distress and health-related quality of life in patients with polycythemia vera or essential thrombocythemia during treatment with interferon-α. Acta Oncologica 2002;41:50-5.
9. Lengfelder E, Berger U, Hehlmann R. Interferon-α in the treatment of polycythemia vera. Ann Hematol 2000;79:103-9.
10. Mazur EM, Rosmarin AG, Sohl PA, Newton JL, Narendran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992;79:1931-7.
11. Bellucci S, Legrand C, Boval B, Drouet L, Caen J. Studies of platelet volume, chemistry and function in patients with essential thrombocythemia treated with anagrelide. Br J Haematol 1999;104:886-92.
12. Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 2002;99:1602-9.
13. Anagrelide study group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992;92:69-78.
14. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 1997;34:41-54.
15. Petrides PE, Beykirch MK, Trapp OM et al. Anagrelide, a novel platelet lowering option in essential thrombocythemia: treatment experience in 48 patients in Germany. Eur J Haematol 1998;61:71-6.
16. Silverstein MN, Tefferi A. Treatment of essential thrombocythemia with anagrelide. Semin Hematol 1999;36:23-5.
17. Zomas A, Marinakis T, Grigoraki V. The use of anagrelide for control of thrombocytosis in Greek patients with myeloproliferative disorders. Haema 2002;5:320-5.
18. Storen, EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-6.
19. Mills AK, Taylor KM, Wright SWJ, Bunce I, Eliadis P, Brigden MC, et al. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Aust N Z J Med 1999;29:29-35.
20. Kutti J, Wadenvik H. Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis. Leuk Lymphoma 1996;22:41-3.
21. Agrylin package insert. Roberts Pharmaceutical Corp., Eatontown, NJ; USA. 1997.
22. Tsimberidou A, Colburn D, Welch M, Cortes J, Verstovsek S, O'Brian S, et al. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol (E-version).
23. Kornblitt LI, Vasallu PS, Heller P, Molinas FC. Treatment of essential thrombocythemia with anagrelide: a three year experience. Medicina 2002;62:231-6.